GALANTAMINE HYDROBROMIDE

Post-LOE

galantamine hydrobromide

Hikma

ANDAORALSOLUTION

Approved

Jan 2009

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

2/8 — Basic

Drug data last refreshed 5h ago

Mechanism of Action

Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (3)

NCT00297362N/ACompleted

A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease

Started Jun 2004

344 enrolled

Alzheimer Disease

NCT00216593Phase 3Completed

Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study

Started Dec 2003

415 enrolled

DementiaAlzheimer Disease

NCT00077727Phase 3Completed

A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.

Started Mar 2003

107 enrolled

Schizophrenia

Company

Worked on GALANTAMINE HYDROBROMIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.